| Synonym |
| Thai / English name |
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kgDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : EquivocalRemark : Drug; On the fourth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; The pharmacokinetic parameters of tolbutamide in rats showed no significant difference among LSG, LLG and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kgDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : PositiveRemark : Drug; On the fourth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; After pretreatment with HSYA, the t1/2 and Tmax of tolbutamide in HSG were increased significantly by 43.5% and 34.0% (P<0.05) compared to those of BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kgDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : EquivocalRemark : Drug; On the eleventh or fifteenth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; The pharmacokinetic parameters of tolbutamide in rats showed no significant difference among LSG, LLG and BCG.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kgDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : PositiveRemark : Drug; On the eleventh or fifteenth day, a cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg), dextromethorphan (20 mg/kg) and midazolam (10 mg/kg) in CMC-Na solution, was administered orally to all rats in each group. Blood samples of each rat were collected pre-dose (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 h after probe drugs administration through the tail vein. Results; The t1/2, Tmax, Cmax and MRT (0-infinity) of tolbutamide in HLG were increased significantly by 74.0%, 53.3%, 45.2%, and 45.9% (P<0.05) compared to those of BCG, CL of tolbutamide in HLG was decreased significantly by 31.2% (P<0.05).Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kg/dayDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : Results; compared with BCG, the mRNA expression level of CYP1A2 in LLG and HLG was significantly decreased to 0.68 and 0.46 times, respectively. Meanwhile, the mRNA expression level of CYP2C11 in HLG was significantly decreased to 0.45 times. These results indicated that CYP1A2 and CYP2C11 enzyme activities were inhibited.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kg/dayDuration : 3 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : Results; compared with BCG, the mRNA expression level of CYP1A2 in LLG and HLG was significantly decreased to 0.68 and 0.46 times, respectively. Meanwhile, the mRNA expression level of CYP2C11 in HLG was significantly decreased to 0.45 times. These results indicated that CYP1A2 and CYP2C11 enzyme activities were inhibited.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 3.0 mg/kg/dayDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Results; compared with BCG, the mRNA expression level of CYP1A2 in LLG and HLG was significantly decreased to 0.68 and 0.46 times, respectively. Meanwhile, the mRNA expression level of CYP2C11 in HLG was significantly decreased to 0.45 times. These results indicated that CYP1A2 and CYP2C11 enzyme activities were inhibited.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
Part Used : ดอกActivity : CYP2C11 INHIBITIONSolvent/Active Compound : Hydroxysafflor yellow A (HSYA)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 12.0 mg/kg/dayDuration : 14 daysType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Results; compared with BCG, the mRNA expression level of CYP1A2 in LLG and HLG was significantly decreased to 0.68 and 0.46 times, respectively. Meanwhile, the mRNA expression level of CYP2C11 in HLG was significantly decreased to 0.45 times. These results indicated that CYP1A2 and CYP2C11 enzyme activities were inhibited.Note : T1/2: half-life; Tmax: the time of peak concentration; Cmax: the peak or maximum concentration; AUC(0-infinity): area under a curve extrapolated to infinity; MRT: mean residence time; CL: the total body clearance; BCG: blank control group; LSG: low dosage (3.0 mg/kg/day) and short period (3 days) group; LLG: low dosage and long period (14 days) group; HSG: high dosage (12.0 mg/kg/day) and short period group; HLG: high dosage and long period group.
